Physical Activity Capture Technology With Potential for Incorporation Into Closed-Loop Control for Type 1 Diabetes.
Physical activity is an important determinant of glucose variability in type 1 diabetes (T1D). It has been incorporated as a nonglucose input into closed-loop control (CLC) protocols for T1D during the last 4 years mainly by 3 research groups in single center based controlled clinical trials involving a maximum of 18 subjects in any 1 study. Although physical activity data capture may have clinical benefit in patients with T1D by impacting cardiovascular fitness and optimal body weight achievement and maintenance, limited number of such studies have been conducted to date. Clinical trial registries provide information about a single small sample size 2 center prospective study incorporating physical activity data input to modulate closed-loop control in T1D that are seeking to build on prior studies. We expect an increase in such studies especially since the NIH has expanded support of this type of research with additional grants starting in the second half of 2015. Studies (1) involving patients with other disorders that have lasted 12 weeks or longer and tracked physical activity and (2) including both aerobic and resistance activity may offer insights about the user experience and device optimization even as single input CLC heads into real-world clinical trials over the next few years and nonglucose input is introduced as the next advance.
Endocrine Research Unit, Mayo Clinic, Rochester, MN, USA.
Vikash
V
Dadlani
Mayo Clinic, Scottsdale, AZ, USA Obesity Solutions, Mayo Clinic Arizona and Arizona State University, Tempe, AZ, USA.
James A
JA
Levine
Endocrine Research Unit, Mayo Clinic, Rochester, MN, USA.
Shelly K
SK
McCrady-Spitzer
Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA, USA.
Eyal
E
Dassau
Endocrine Research Unit, Mayo Clinic, Rochester, MN, USA kudva.yogish@mayo.edu.
Yogish C
YC
Kudva
D056044:Actigraphy / Q000295:instrumentation*; D000465:Algorithms; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004867:Equipment Design; D015444:Exercise; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems; D009043:Motor Activity; D019397:Pancreas, Artificial; D011237:Predictive Value of Tests; D012815:Signal Processing, Computer-Assisted; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin
closed loop; glucose insulin; physical activity capture devices; type 1 diabetes